Opioid use disorder during pregnancy presents a profoundly complex clinical challenge marked by the necessity to balance effective addiction treatment with the safety of both mother and fetus. Traditional sublingual buprenorphine, administered daily beneath the tongue, has been the standard pharmacologic approach due to its efficacy in reducing illicit opioid use. However, sublingual treatment has notable limitations, including risks of medication misuse, adherence challenges, and pharmacokinetic fluctuations that cause daily peaks and troughs in blood levels. These fluctuations may inadequately suppress opioid cravings and withdrawal symptoms, potentially leading to intermittent use of illicit opioids during pregnancy.

The NIH-supported multicenter randomized clinical trial enrolled 140 pregnant participants diagnosed with OUD, who were randomized to receive either weekly subcutaneous extended-release buprenorphine injections or standard daily sublingual buprenorphine, with or without naloxone. The extended-release formulation, administered under the skin, offers a pharmacologically stable delivery system that maintains therapeutic buprenorphine plasma concentrations consistently throughout the week. Postpartum participants who were not breastfeeding were given the option to receive monthly extended-release treatments, thereby extending the study’s relevance beyond pregnancy into the critical postpartum period.

Urine drug screenings served as the objective metric for opioid abstinence throughout gestation and up to 12 months postpartum. Analysis revealed that participants receiving the weekly extended-release injections exhibited significantly higher rates of opioid abstinence during pregnancy when compared to the sublingual cohort. Importantly, these superior abstinence rates persisted into the postpartum period, where extended-release therapy was shown to be non-inferior. This finding addresses a major clinical need, as postpartum relapse in OUD is a considerable risk due to factors such as stress, physiological changes, and the demands of new motherhood.

Safety outcomes also favored the extended-release group. Although non-serious adverse events were comparably frequent between both groups, those events in the extended-release cohort were more frequently attributed to the medication itself during pregnancy. Contrastingly, serious maternal adverse events were significantly less common among those receiving injectable buprenorphine throughout the entire study period. The reduction in severe adverse events underscores the enhanced tolerability and potential safety benefits of the extended-release formulation, which may translate into fewer interruptions or discontinuations of therapy in clinical practice.

A crucial concern in managing OUD during pregnancy is the risk of neonatal opioid withdrawal syndrome (NOWS), a condition characterized by withdrawal symptoms in newborns exposed to opioids in utero. This trial found no statistically significant differences in NOWS outcomes between the injectable and sublingual treatment groups. This equivalency suggests that extended-release buprenorphine does not increase harm to neonates compared to traditional treatment, while simultaneously offering superior maternal opioid abstinence benefits.

Beyond its clinical implications, this trial marks a significant methodological milestone as the first randomized controlled study to evaluate extended-release buprenorphine specifically in pregnant and postpartum populations. Prior evidence had established the efficacy of extended-release formulations in non-pregnant adults, but this direct assessment during pregnancy is critical given the unique physiological, pharmacokinetic, and psychosocial factors in this demographic.

Mechanistically, the pharmacokinetics of extended-release buprenorphine enable a steady-state plasma concentration that mitigates the classic peak-trough fluctuations seen with sublingual dosing. This steady exposure more effectively attenuates opioid withdrawal symptoms and cravings, likely contributing to the enhanced abstinence observed. Furthermore, the weekly injection reduces the burden of daily dosing adherence, lowering the risk of missed doses or medication diversion, and thus potentially decreasing illicit opioid use.

Clinicians treating pregnant patients with OUD often face challenges with maintaining consistent adherence to daily medications. The extended-release injectable formulation presents a promising intervention to address this obstacle by simplifying treatment regimens and providing sustained medication coverage. This can enhance treatment retention and support more stable recovery trajectories during the vulnerable prenatal and postpartum timeframes.

The broader public health implications of these findings are substantial. The opioid overdose crisis remains a dire emergency in the United States and globally, with pregnant populations being particularly vulnerable to adverse outcomes. Improving treatment modalities that not only ensure maternal safety but also reduce fetal and neonatal risks is paramount. By validating extended-release buprenorphine’s safety and superior efficacy, this trial empowers clinicians and policymakers to incorporate this formulation into standard care guidelines for managing OUD in pregnancy.

This study also highlights the importance of ongoing NIH-funded research efforts within the NIH Helping to End Addiction Long-term® (NIH HEAL®) Initiative, which targets innovative strategies to combat substance use disorders. The clinical trial’s design, involving randomized allocation and robust follow-up through 12 months postpartum, exemplifies rigorous research methodologies essential for generating actionable evidence in complex populations.

In conclusion, the adoption of weekly injectable extended-release buprenorphine for pregnant individuals with OUD offers a transformative enhancement over daily sublingual administration. Its ability to achieve higher opioid abstinence rates safely, coupled with a comparable neonatal risk profile, positions this treatment as a vital weapon in the fight against the opioid epidemic affecting mothers and infants alike. Future research will be necessary to optimize dosing strategies, evaluate long-term maternal and child outcomes, and expand access to this therapy across diverse healthcare settings.

Subject of Research: Extended-release versus sublingual buprenorphine treatment efficacy and safety in opioid use disorder during pregnancy and postpartum.

Article Title: Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum

News Publication Date: 16-Mar-2026

Web References:
https://doi.org/10.1001/jamainternmed.2026.0057
https://www.nih.gov/heal
https://www.nida.nih.gov

References:
TJ Winhusen, et al. Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum. JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2026.0057

Keywords: opioid use disorder, pregnancy, extended-release buprenorphine, sublingual buprenorphine, neonatal opioid withdrawal syndrome, clinical trial, pharmacokinetics, addiction treatment, maternal health, postpartum, drug adherence, NIH HEAL Initiative

Buprenorphine, a partial agonist at the mu-opioid receptor, has gained prominence in treating opioid use disorder due to its unique pharmacological profile. It helps mitigate withdrawal symptoms and cravings while offering a ceiling effect that reduces the risk of overdose. Despite this, traditional forms of buprenorphine, particularly sublingual formulations, often face challenges in achieving optimal adherence and retention among users. Extended-release preparations, on the other hand, promise to enhance adherence by simplifying the dosing schedule—potentially providing sustained therapeutic effects with less frequent administration.

This randomized comparison is crucial, as the jail population—the target group of this study—faces unique challenges. Often caught in a cycle of addiction and criminal justice involvement, these individuals experience higher rates of opioid use and a significant risk of withdrawal symptoms during incarceration. The study aims to investigate whether the extended-release formulation can provide superior outcomes in terms of retention and overall opioid use reduction compared to the more traditional sublingual method.

The proposed trial will involve a rigorous methodology, incorporating randomized assignment to either the extended-release or sublingual buprenorphine group. Participants will be monitored closely to evaluate objective measures of treatment efficacy, including reductions in opioid use as determined by urine toxicology screens and self-reported use. Retention rates, another key performance indicator, will be analyzed to assess which formulation better engages participants in the treatment process. Furthermore, the team plans to collect qualitative data to enhance understanding of the participants’ experiences and preferences regarding the two treatment modalities.

A notable aspect of this research is its alignment with the broader public health goal of improving outcomes for vulnerable populations. Buprenorphine treatment can be pivotal in breaking the cycle of addiction and reducing recidivism. By focusing on individuals in jails—who often have limited access to addiction services—this trial aims to bridge treatment gaps that are prevalent in the current healthcare landscape. The findings could inform policymakers and healthcare leaders on how to optimize care for those experiencing the intersection of addiction and justice involvement.

The lag in treatment access for incarcerated individuals is alarming, given that opioid use disorders are escalating at an unprecedented rate. As opioid fatalities continue to surge across the United States, it is vital to address the needs of all affected individuals, regardless of their legal status. By providing evidence of the comparative efficacy of buprenorphine formulations, this study could catalyze changes in how healthcare is delivered within correctional facilities, a traditionally stigmatized environment regarding addiction treatment.

In addition to therapeutic comparisons, the study will also scrutinize how socio-environmental factors influence treatment retention and efficacy. Factors such as the perceived stigma associated with drug use, the emotional and psychological burdens of incarceration, and access to supportive social networks may all significantly affect the outcomes of buprenorphine treatment. This holistic approach positions the study not only as a comparison of two pharmacological strategies but also as an exploration of the socio-behavioral dynamics that underpin addiction treatment in jails.

The researchers are approaching this study with a strong multidisciplinary perspective, integrating insights from addiction medicine, psychiatry, social work, and criminal justice. This collaborative framework aims to foster a comprehensive understanding of the barriers and facilitators to effective treatment among pre-trial detainees. By incorporating diverse expertise, the team hopes to develop interventions that are contextually relevant, pragmatic, and ultimately effective in reducing both substance use and the negative health outcomes associated with it.

The anticipated impact of this study extends beyond the immediate population under investigation. Should the extended-release formulation demonstrate superior efficacy, it may set a precedent for its implementation in other high-risk groups, including those not involved in the criminal justice system. The research could help reshape how buprenorphine is utilized in various treatment programs, paving the way for innovative approaches that cater to diverse populations confronting opioid use disorders.

Moreover, the findings may incite broader conversations about the integration of addiction treatment into correctional settings. If successful, this trial could serve as a model for other facilities, not merely in the U.S. but globally. The ability to offer effective treatment during incarceration could signify a shift in the paradigm of how society addresses addiction—a transition from punitive measures toward healthcare-driven solutions that acknowledge addiction as a public health crisis rather than merely a legal issue.

The study is set to advance our understanding of the potential benefits of extended-release buprenorphine in a population that has historically been underserved. The findings could inform future clinical guidelines and shape policies that advocate for the rights and health of incarcerated individuals. As jurisdictions grapple with rising opioid-related deaths, innovative and effective treatment strategies could become paramount to improving public health outcomes and mitigating the devastating effects of the opioid crisis.

In conclusion, Rottapel and colleagues are poised to contribute significantly to addiction medicine through their planned trial comparing extended-release and sublingual buprenorphine for pre-trial detainees. By focusing on this marginalized group and addressing the multifaceted challenges they face, this research could not only enhance our understanding of effective treatments but also catalyze meaningful changes in how addiction is treated in the context of incarceration, ultimately saving lives in the process.

Subject of Research: Randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail.

Article Title: A protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail.

Article References: Rottapel, R.E., Stopka, T.J., Friedmann, P.D. et al. A protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail. Addict Sci Clin Pract 20, 88 (2025). https://doi.org/10.1186/s13722-025-00611-9

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13722-025-00611-9

Keywords: Buprenorphine, opioid use disorder, pre-trial detainees, randomized clinical trial, addiction medicine, jail healthcare, treatment adherence.